Compare ARK Genomic Revolution ETF (ARKG) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Estee Lauder Companies Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.31, while Estee Lauder Companies Inc trades at $87.79 (market cap $31.54B). The key difference: Estee Lauder Companies Inc pays a 1.61% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Estee Lauder Companies Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | EL | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $44.55 | $119.61 |
52-Week Low | $24.02 | $67.23 |
Market Cap | — | $31.54B |
Enterprise Value | — | $37.72B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
Estée Lauder (EL) trades at $88.35, up 3.35% with a bullish technical signal and recent earnings beats. The stock shows strong institutional interest with Bank of America increasing its stake by 950.9% in Q1 2026. Despite negative net income margins, the company maintains a robust gross margin of 74.71% and has upcoming Q2 2026 earnings expected at $0.3197 per share. Recent corporate developments include a new fragrance launch and executive appointments.
The outlook remains cautiously optimistic with a consensus price target of $91.67 offering 3.8% upside potential. Key risks include declining revenue trends and negative profitability, while opportunities lie in product innovation and digital engagement. The stock faces resistance near $90-$93 levels with support at $86.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
